Indian drugmaker Biocon aims to be the world's top insulin supplier within five years, capitalising on growing demand as major pharmaceutic...

Indian pharma is shifting from generics to innovation. This transformation, extending to 2035, is creating significant new opportunities. C...

Rising demand for weight-loss drugs, cosmetic procedures and wellness treatments is creating a growing out-of-pocket healthcare expense cat...

India's market for cheaper anti-obesity drugs has surged tenfold. While demand is high, especially among those with diabetes, concerns abou...

Britain's medicine regulator has approved Novo Nordisk's weight-loss pill. This makes the UK the first European market for the oral treatme...

Households with at least one user of GLP-1 weight-loss drugs bought 299 million fewer food items in the year after adoption of the medicati...

The landscape of India's anti-obesity drug market has reached a point of refinement. While there are affordable generic options, their upta...

Hyderabad's Hetero Labs partners with European giant Gedeon Richter. They will jointly develop and sell Semaglutide Injection, the generic ...

India's anti-obesity drug market sees a slowdown after initial generic semaglutide sales. Demand has eased from its peak, with growth moder...

Eli Lilly presented trial results for its new obesity drug retatrutide. The drug significantly reduced sleep apnea severity and knee osteoa...

Forecasts for FY27 suggest a modest rise in bad loans for microfinance institutions, a development stemming from the adjustments following ...

Yum Brands is reportedly in exclusive talks with private-equity firm LongRange Capital for a potential sale of its Pizza Hut chain. This mo...

Bio Medica Laboratories' shares are set to list on the NSE SME platform amidst weak grey market sentiment, with the IPO currently trading a...

Market expert Daljeet Kohli advises investors to focus on quality stocks at discounted prices, rather than the Nifty's movement. He highlig...

Demand for vitamin and nutritional supplements is surging in India. This trend follows the increased availability of semaglutide-based weig...

The notice issued by the Central Drugs Standard Control Organisation (CDSCO) cites provisions of the Drugs and Cosmetics Act, 1940, and the...

Dr. Reddy's Laboratories proudly presents Obeda, a groundbreaking oral semaglutide biosimilar for managing Type 2 diabetes in India. This i...